United States Food and Drug Administration (USFDA) has concluded an inspection at Alembic Pharmaceuticals’ Bioequivalence facility located at Vadodara. The inspection was conducted from March 03, 2025 to March 07, 2025. This was a scheduled inspection. The USFDA issued a form 483 with one procedural observation.
The Company will provide comprehensive response to USFDA for the observations within the stipulated period. The Company is committed to maintain the highest quality standards and compliance at all times.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1670.05 |
| Dr. Reddys Lab | 1223.90 |
| Cipla | 1230.70 |
| Zydus Lifesciences | 929.55 |
| Lupin | 2325.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: